Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group Study Journal Article

   

Authors:	Tan, C. R.; Asoori, S.; Huang, C. Y.; Brunaldi, L.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Bansal, R.; Silva Corraes, A. D. M.; Chhabra, S.; Parrondo, R.; Ailawadhi, S.; Fotiou, D.; Dimopoulos, M. A.; Yong, K.; Mactier, C.; Lau, C.; Corona, M.; Marin, A. J. S.; Mian, H.; Durie, B. G. M.; Usmani, S. Z.; Martin, T. G.; Lin, Y.
Article Title:	Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group Study
Abstract:	Teclistamab, a BCMAxCD3-directed bispecific antibody, has shown high response rates and durable remissions in triple-class-exposed patients with relapsed/refractory multiple myeloma. We performed a retrospective study evaluating the efficacy and safety of teclistamab in 210 patients treated at 9 academic centers from five countries within the IMWG Immunotherapy Working Group Committee. Patients were heavily pretreated, with 83% having triple-class refractory disease and 44% with prior BCMA-targeted therapy. With a median follow-up of 5.3 months, the overall response rate (ORR) was 67% in 188 response-evaluable patients, including 55% with a very good partial response or better. The 6-month progression-free survival (PFS) and overall survival rates were 53% (95% CI, 46–61%) and 73% (67–80%), respectively. Patients who received prior BCMA-directed therapy compared to BCMA-treatment-naïve patients had a lower ORR (58.3 vs 74.0%; P = 0.03) and PFS (6-month PFS 43% [95% CI, 33–55%] vs 63% [54–73%]; logrank P = 0.004). Step-up dosing occurred in an outpatient setting for 23% of patients. CRS occurred in 54% of patients, and infections were reported in 56.2% of patients, with 22% having grade ≥3 infections. In this multicenter real-world study, we found that teclistamab can lead to rapid responses in heavily pretreated myeloma patients with comparable efficacy and safety profiles, as demonstrated in MajesTEC-1. © The Author(s) 2025.
Keywords:	adult; controlled study; treatment outcome; treatment response; aged; aged, 80 and over; middle aged; retrospective studies; major clinical study; overall survival; clinical trial; mortality; neutropenia; cancer recurrence; drug safety; comparative study; neurotoxicity; follow up; progression free survival; multiple myeloma; bleeding; thrombocytopenia; cohort analysis; creatinine; immunoglobulin; steroid; herpes simplex; herpes zoster; drug screening; pathology; retrospective study; pneumonia; immunotherapy; multicenter study; prophylaxis; antivirus agent; clostridium difficile infection; drug therapy; immunoglobulin deficiency; cytomegalovirus infection; parainfluenza virus infection; enterococcal infection; upper respiratory tract infection; creatinine clearance; thrombocyte transfusion; steroid therapy; viremia; cytokine release syndrome; antibodies, bispecific; refractory cancer; tocilizumab; bispecific antibody; escherichia coli infection; asymptomatic infection; norovirus infection; rhinovirus infection; very elderly; humans; human; male; female; article; klebsiella infection; pseudomonas infection; b cell maturation antigen; monoclonal antibody therapy; immunological antineoplastic agent; antineoplastic agents, immunological; antibody drug conjugate; chimeric antigen receptor t-cell immunotherapy; respiratory syncytial virus infection; coronavirus disease 2019; teclistamab; relapsed refractory multiple myeloma
Journal Title:	Blood Cancer Journal
Volume:	15
ISSN:	2044-5385
Publisher:	Nature Publishing Group
Date Published:	2025-04-03
Start Page:	53
Language:	English
DOI:	10.1038/s41408-025-01259-z
PUBMED:	40175336
PROVIDER:	scopus
PMCID:	PMC11965530
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-105001687425&doi=10.1038%2fs41408-025-01259-z&partnerID=40&md5=e7edbf5acce35a00b8c90af324159821
Notes:	Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Carlyn Tan -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/224569